Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|December 17, 2020
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor ActivityJohannes Sam, Sara Colombetti, Tanja Fauti, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacyGabrielle Leclercq, Hélène Haegel, Alberto Toso, et al.
Mabs|November 6, 2025
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Anneliese Schneider, Inja Waldhauer, et al.
Antimicrobial Resistance and Infection Control|January 18, 2022
Risk factors for nosocomial SARS-CoV-2 infections in patients: results from a retrospective matched case-control study in a tertiary care university centerSeven Johannes Sam Aghdassi, Frank Schwab, Luis Alberto Peña Diaz, et al.
Nature Communications|June 26, 2020
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibodyMartina Geiger, Kay-Gunnar Stubenrauch, Johannes Sam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific AntibodiesGabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2025
Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrowEsen Sefik, William Philbrick, Fengrui Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesMarina Bacac, Sara Colombetti, Sylvia Herter, et al.
Blood|August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphomaJohannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.
Pageof 7